Your browser doesn't support javascript.
loading
An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers.
Premi, Enrico; Costa, Tommaso; Gazzina, Stefano; Benussi, Alberto; Cauda, Franco; Gasparotti, Roberto; Archetti, Silvana; Alberici, Antonella; van Swieten, John C; Sanchez-Valle, Raquel; Moreno, Fermin; Santana, Isabel; Laforce, Robert; Ducharme, Simon; Graff, Caroline; Galimberti, Daniela; Masellis, Mario; Tartaglia, Carmela; Rowe, James B; Finger, Elizabeth; Tagliavini, Fabrizio; de Mendonça, Alexandre; Vandenberghe, Rik; Gerhard, Alexander; Butler, Chris R; Danek, Adrian; Synofzik, Matthis; Levin, Johannes; Otto, Markus; Ghidoni, Roberta; Frisoni, Giovanni; Sorbi, Sandro; Peakman, Georgia; Todd, Emily; Bocchetta, Martina; Rohrer, Johnathan D; Borroni, Barbara.
Afiliação
  • Premi E; Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Costa T; Stroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Spedali Civili Hospital, Brescia, Italy.
  • Gazzina S; Focus Lab, Department of Psychology, University of Turin, Turin, Italy.
  • Benussi A; GCS-FMRI, Koelliker Hospital and Department of Psychology, University of Turin, Turin, Italy.
  • Cauda F; Neuroscience Institute of Turin, University of Turin, Turin, Italy.
  • Gasparotti R; Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Archetti S; Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Alberici A; Focus Lab, Department of Psychology, University of Turin, Turin, Italy.
  • van Swieten JC; GCS-FMRI, Koelliker Hospital and Department of Psychology, University of Turin, Turin, Italy.
  • Sanchez-Valle R; Neuroscience Institute of Turin, University of Turin, Turin, Italy.
  • Moreno F; Neuroradiology Unit, University of Brescia, Brescia, Italy.
  • Santana I; Biotechnology Laboratory, Department of Diagnostic, Spedali Civili Hospital, Brescia, Italy.
  • Laforce R; Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Ducharme S; Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands.
  • Graff C; Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain.
  • Galimberti D; Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain.
  • Masellis M; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain.
  • Tartaglia C; Neurology Department, Centro Hospitalar e Universitário de Coimbra, Portugal.
  • Rowe JB; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
  • Finger E; Centre of Neurosciences and Cell biology, Universidade de Coimbra, Coimbra, Portugal.
  • Tagliavini F; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, Faculté de Médecine, CHU de Québec-Université Laval, QC, Canada.
  • de Mendonça A; Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, QC, Canada.
  • Vandenberghe R; McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
  • Gerhard A; Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.
  • Butler CR; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.
  • Danek A; Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Milan, Italy.
  • Synofzik M; Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
  • Levin J; Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, ON, Canada.
  • Otto M; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Ghidoni R; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Frisoni G; Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.
  • Sorbi S; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy.
  • Peakman G; Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
  • Todd E; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • Bocchetta M; Neurology Service, University Hospitals Leuven, Belgium.
  • Rohrer JD; Leuven Brain Institute, KU Leuven, Leuven, Belgium.
  • Borroni B; Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
J Alzheimers Dis ; 86(1): 205-218, 2022.
Article em En | MEDLINE | ID: mdl-35068455
BACKGROUND: Magnetic resonance imaging (MRI) measures may be used as outcome markers in frontotemporal dementia (FTD). OBJECTIVES: To predict MRI cortical thickness (CT) at follow-up at the single subject level, using brain MRI acquired at baseline in preclinical FTD. METHODS: 84 presymptomatic subjects carrying Granulin mutations underwent MRI scans at baseline and at follow-up (31.2±16.5 months). Multivariate nonlinear mixed-effects model was used for estimating individualized CT at follow-up based on baseline MRI data. The automated user-friendly preGRN-MRI script was coded. RESULTS: Prediction accuracy was high for each considered brain region (i.e., prefrontal region, real CT at follow-up versus predicted CT at follow-up, mean error ≤1.87%). The sample size required to detect a reduction in decline in a 1-year clinical trial was equal to 52 subjects (power = 0.80, alpha = 0.05). CONCLUSION: The preGRN-MRI tool, using baseline MRI measures, was able to predict the expected MRI atrophy at follow-up in presymptomatic subjects carrying GRN mutations with good performances. This tool could be useful in clinical trials, where deviation of CT from the predicted model may be considered an effect of the intervention itself.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência Frontotemporal Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência Frontotemporal Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article